TGF beta inhibitors / Rigel - LARVOL DELTA

Expanding the mutation and phenotype spectrum of MYH3-associated skeletal disorders. (PubMed, NPJ Genom Med) - "In conclusion, the identification of 12 novel pathogenic variants and overlapping phenotypes in 17 affected individuals from 10 unrelated families expands the mutation and phenotype spectrum of MYH3-associated skeletal disorders. We show that disturbances of canonical or non-canonical TGF-β signaling pathways are involved in pathogenesis of MYH3-associated skeletal fusion (MASF) syndrome."

Journal • SMAD3 • TGFB1

[VIRTUAL] Noncanonical PAR-1 Signalling Leads to Profibrotic Effects in Podocytes in Response to Steroid-Resistant Nephrotic Syndrome Disease Plasma (KIDNEY WEEK 2020) - " Conditionally immortalised human podocytes (ciPods) were treated with PAR-1 agonist peptide or post-transplant SRNS relapse and paired-remission plasma with or without PAR-1 antagonists, RWJ 56110, SCH 79797, Vorapaxar, and FR171113...These changes were inhibited by co-incubation of ciPods with certain PAR-1 inhibitors, but not by TGFb1 inhibitor... We propose that the SRNS circulating factor acts as a pro-fibrotic effector that can activate PAR-1 leading to increased podocyte injury. A greater understanding of these signalling pathways will lead to the identification of novel therapeutic targets for this disease."

Fibrosis • Glomerulonephritis • Nephrology • Renal Disease • Transplantation • MAPK8 • TGFB1

Gap junction-mediated MiR-200b on osteogenesis and angiogenesis in coculture between MSCs and HUVECs. (PubMed, J Cell Sci) - "By adding TGF-β inhibitor SB431542 or neutralizing antibody, the formation of capillary-like structure in coculture could be partially rescued. These findings may be fundamental to the development of cell-based bone regeneration strategy."

Journal • Preclinical